文献速递肝病

司美格鲁肽2.4 mg用于代谢功能障碍相关脂肪性肝炎参与者:3期ESSENCE试验的基线特征与设计

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2024-10-16

ESSENCE是一项两部分、3期、随机、多中心试验,评估皮下司美格鲁肽2.4 mg在活检证实的MASH且纤维化2或3期参与者中的效果。本文报告前800名随机参与者的基线特征:平均年龄56岁,57.1%为女性,平均BMI 34.6 kg/m2,55.5%有2型糖尿病,>99%至少有一项MASLD心血管代谢标准。

要点

  • ESSENCE试验评估司美格鲁肽2.4 mg对活检证实MASH且纤维化2或3期参与者的疗效。
  • 前800名参与者中,纤维化2期250例(31.3%),纤维化3期550例(68.8%)。
  • 尽管MASLD心血管代谢标准不是入组要求,>99%的参与者至少有一项。

核心结论

  • ESSENCE基线人群包括具有临床显著纤维化2期和3期的参与者。
  • 尽管MASLD心血管代谢标准不是研究入组要求,几乎所有参与者(>99%)至少有一项MASLD心血管代谢标准。

研究设计与样本

  • ESSENCE是一项两部分、3期、随机、多中心试验,评估皮下司美格鲁肽2.4 mg在活检证实的MASH且纤维化2或3期参与者中的效果。
  • 第一部分主要目标为证明司美格鲁肽相比安慰剂改善肝脏组织学,两个主要终点为:脂肪性肝炎缓解且肝纤维化无恶化,以及肝纤维化改善且脂肪性肝炎无恶化。
  • 第二部分目标基于临床结局。
  • 当前工作报告前800名随机参与者的基线特征,包括人口统计学、实验室参数、肝脏组织学、无创检测以及MASLD心血管代谢标准的存在情况。

主要发现

  • 800名参与者中,250名(31.3%)为纤维化2期,550名(68.8%)为纤维化3期。
  • 总体人群中,平均(标准差[SD])年龄为56(11.6)岁,57.1%为女性,平均(SD)体重指数为34.6(7.2)kg/m2,55.5%有2型糖尿病,>99%至少有一项MASLD心血管代谢标准(根据已发表定义)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction-associated steatohepatitis (MASH). AIMS: To describe the trial design and baseline characteristics of the 'Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis' (ESSENCE) trial (NCT04822181). METHODS: ESSENCE is a two-part, phase 3, randomised, multicentre trial evaluating the effect of subcutaneous semaglutide 2.4 mg in participants with biopsy-proven MASH and fibrosis stage 2 or 3. The primary objective of Part 1 is to demonstrate that semaglutide improves liver histology compared with placebo. The two primary endpoints are: resolution of steatohepatitis and no worsening of liver fibrosis, and improvement in liver fibrosis and no worsening of steatohepatitis. The Part 2 objective is based on clinical outcomes. The current work reports baseline characteristics of the first 800 randomised participants which includes demographics, laboratory parameters, liver histology, non-invasive tests and presence of metabolic dysfunction-associated steatotic liver disease (MASLD) cardiometabolic criteria. RESULTS: Of 800 participants, 250 (31.3%) had fibrosis stage 2 and 550 (68.8%) had fibrosis stage 3. In the overall population, mean (standard deviation [SD]) age was 56 (11.6) years, 57.1% were female, mean (SD) body mass index was 34.6 (7.2) kg/m2, 55.5% had type 2 diabetes and > 99% had at least one MASLD cardiometabolic criterion according to the published definition. CONCLUSION: The ESSENCE baseline population includes participants with clinically significant fibrosis stages 2 and 3. Although MASLD cardiometabolic criteria were not a requirement for study enrolment, almost all participants (> 99%) had at least one MASLD cardiometabolic criterion. TRIAL REGISTRATION: NCT04822181.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024. PMID: 39412509. doi:10.1111/apt.18331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。